Susan Clark

Prof. Susan Clark


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2018 in Colorectal Disease
Verified
Journal Article
Open access
PDF file
SBS. R. Brown
S. R. Brown
NFN. S. Fearnhead
N. S. Fearnhead
OFO. D. Faiz
O. D. Faiz
JAJ. F. Abercrombie
J. F. Abercrombie
AAA. G. Acheson
A. G. Acheson
ACACPGBI IBD Surgery Consensus Collaboration
ACPGBI IBD Surgery Consensus Collaboration
Aim: There is a requirement of an expansive and up to date review of surgical management of inflammatory bowel disease (IBD) that can dovetail with the medical guidelines produced by the British Society of Gastroenterology.Methods: Surgeons who are members of theACPGBIwith a recognised interest inIBDwere invited to contribute various sections of the guidelines. They were directed to produce a procedure based document using literature searches that were systematic, comprehensible, transparent and reproducible. Levels of evidence were graded. An editorial board was convened to ensure consistency of style, presentation and quality. Each author was asked to provide a set of recommendations which were evidence based and unambiguous. These recommendations were submitted to the whole guideline group and scored. They were then refined and submitted to a second vote. Only those that achieved >80% consensus at level 5 (strongly agree) or level 4 (agree) after 2 votes were included in the guidelines.Results: All aspects of surgical care forIBDhave been included along with 157 recommendations for management.Conclusion: These guidelines provide an up to date and evidence based summary of the current surgical knowledge in the management ofIBDand will serve as a useful practical text for clinicians performing this type of surgery.

1 January 2015 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MUMallikarjuna Uppara
Mallikarjuna Uppara
FAFranklin Adaba
Franklin Adaba
AAAlan Askari
Alan Askari
SCSusan Clark
Susan Clark
GHGeorge B. Hanna
George B. Hanna
OFOmar Faiz
Omar Faiz
Screening programmes exist in many countries for colorectal cancer. In recent years, there has been a drive for a non-invasive screening marker of higher sensitivity and specificity. Stool-based pyruvate kinase isoenzyme M2 (M2-PK) is one such biomarker under investigation. The aim of this systematic review and meta-analysis is to determine the diagnostic accuracy, sensitivity and specificity of M2-PK as a screening tool in colorectal cancer. A literature search of Ovid Medline, EMBASE and Google Scholar was carried out. The search strategy was restricted to human subjects and studies published in English. Data on sensitivity and specificity were extracted and pooled. Statistical analysis was conducted using summary receiver operating characteristic (SROC) curve methodology. A total of eight studies were suitable for data synthesis and analysis. Our analysis showed a pooled sensitivity and specificity for M2-PK to be 79% (CI 73%–83%) and 80% (CI 73%–86%), respectively. The accuracy of M2-PK was 0.85(0.82–0.88). Faecal M2-PK assay has a relatively good sensitivity and specificity and high accuracy for screening colorectal cancer.

1 January 2012
Verified
Open access
VTVera N. Tudyka
Vera N. Tudyka
SCSusan Clark
Susan Clark
Familial adenomatous polyposis (FAP) is a dominantly inherited condition caused by germline mutation of the APC gene resulting in formation of numerous large bowel adenomas in late childhood or adolescence. Unless these are removed, colorectal cancer inevitably develops. Prophylactic surgical treatment is required to prevent this. In surgical decision making, considerations should include genotype-phenotype correlation, perioperative morbidity and risk of impaired sexual and reproductive function in young patients after major pelvic surgery. Colectomy with ileorectal anastomosis remains an appropriate prophylactic procedure in many patients. However, in those with high-density polyposis or a genotype predictive of aggressive disease, restorative proctocolectomy is preferable. There is a range of other features, as FAP is essentially a systemic disease. These include duodenal and peri-ampullary adenomas and carcinoma, desmoid tumors, papillary-type thyroid carcinoma and pancreatic carcinoma among others. With improved management that reduces the risk of colorectal cancer, these extracolonic manifestations have become of increasing clinical significance. For all FAP patients, including those undergoing proctocolectomy, thorough surveillance is of vital importance as there remains a risk of developing neoplasia. Despite advances in surgical techniques, screening and surveillance, life expectancy in patients with FAP is still less than that of the general population.

1 February 1997 in The Lancet
Verified
Journal Article
Closed access
SCSusan Clark
Susan Clark
KPKevin Pack
Kevin Pack
JPJon Pritchard
Jon Pritchard
SHShirley V Hodgson
Shirley V Hodgson

1 June 2019 in The Surgeon
Verified
Journal Article
Closed access
SCSusan Clark
Susan Clark

1 May 2016 in Oncoscience
Verified
Journal Article
Open access
SWSarah-Jane Walton
Sarah-Jane Walton
ALAmy Lewis
Amy Lewis
RJRosemary Jeffery
Rosemary Jeffery
HTHannah Thompson
Hannah Thompson
RFRoger Feakins
Roger Feakins
ASAndrew Silver
Andrew Silver
Familial adenomatous polyposis (FAP) is rare affecting 1 in 10,000 people and a subset (10%) are at risk of myofibroblastic desmoid tumours (DTs) after colectomy to prevent cancer. DTs are a major cause of morbidity and mortality. The absence of markers to monitor progression and a lack of treatment options are significant limitations to clinical management. We investigated microRNAs (miRNA) levels in DTs and serum using expression array analysis on two independent cohorts of FAP patients (total, n=24). Each comprised equal numbers of patients who had formed DTs (cases) and those who had not (controls). All controls had absence of DTs confirmed by clinical and radiological assessment over at least three years post- colectomy. Technical qPCR validation was performed using an expanded cohort (29 FAP patients; 16 cases and 13 controls). The most significant elevated serum miRNA marker of DTs was miR-34a-5p and in-situ hybridisation (ISH) showed most DTs analysed (5/6) expressed miRNA-34a-5p. Exome sequencing of tumour and matched germline DNA did not detect mutations within the miR-34a-5p transcript sites or 3′-UTR of target genes that would alter functional miRNA activity. In conclusion, miR-34a-5p is a potential circulatory marker and therapy target. A large prospective world-wide multi-centre study is now warranted.